Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.60 |
| ▸ | MMP1 | P03956 | 5/20 | 0.57 |
| ▸ | MMP8 | P22894 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043174 | 0.85 | MMP13 (0.63) | MMP13MMP1MMP8PKMELOVL6 | |
| SCHEMBL1188309 | 0.82 | MMP13 (0.73) | MMP13MMP1MMP8PKMELOVL6 | |
| SCHEMBL19693181 | 0.81 | ELOVL6 (0.50) | MMP13ELOVL6CA1CA2HSD11B1 | |
| SCHEMBL8438391 | 0.79 | MMP13 (0.74) | MMP13MMP1MMP8PKMMMP9 | |
| SCHEMBL25315126 | 0.78 | LMNA (0.45) | MMP13MMP1MMP8PKMMMP9 | |
| SCHEMBL25315121 | 0.78 | LMNA (0.45) | MMP13MMP1MMP8PKMMMP9 | |
| SCHEMBL27529540 | 0.77 | MMP13 (0.68) | MMP13MMP1MMP8PKMMMP9 | |
| SCHEMBL26027367 | 0.76 | MAPK1 (0.48) | MMP13MMP1MMP8MMP9MMP3 | |
| SCHEMBL17966724 | 0.76 | MMP13 (0.56) | MMP13MMP1MMP8PKMELOVL6 | |
| SCHEMBL10795088 | 0.75 | MMP13 (0.59) | MMP13MMP1MMP8PKMMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | MMP13 979/4885MMP1 1414/4885MMP8 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.